A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs IRL 790 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 05 Dec 2017 Status changed from planning to not yet recruiting.
- 27 Nov 2017 New trial record
- 17 Aug 2017 According to a Integrative Research Laboratories media release, the company has signed an agreement with The Clinical Trial Company Ltd (TCTC) to conduct this trial in Autumn 2017.